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O-GlcNAcylation is an essential posttranslational modiﬁcation in metazoa. Modulation of O-GlcNAc
levels with small molecule inhibitors of O-GlcNAc hydrolase (OGA) is a useful strategy to probe the
role of this modiﬁcation in a range of cellular processes. Here we report the discovery of novel, low
molecular weight and drug-like O-GlcNAcase inhibitor scaffolds by high-throughput screening.
Kinetic andX-ray crystallographic analyses of the bindingmodeswith human/bacterialO-GlcNAcases
identify some of these as competitive inhibitors. Comparative kinetic experiments with the mecha-
nistically related human lysosomal hexosaminidases reveal that three of the inhibitor scaffolds show
selectivity towards human OGA. These scaffolds provide attractive starting points for the develop-
ment of non-carbohydrate, drug-like OGA inhibitors.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The posttranslational modiﬁcation of intracellular proteins with
O-linked N-acetylglucosamine (O-GlcNAc) was discovered 25 years
ago by Torres and Hart [1], breaking the dogma that protein glyco-
sylation was restricted to the endoplasmic reticulum, Golgi appa-
ratus, cell surface and extracellular matrix [2]. O-GlcNAc
modiﬁed proteins are found mostly in the nucleoplasm, cytoplasm
and to some extent in the mitochondria, and are not further ex-
tended by glycosylation. Similar to protein phosphorylation, the
O-GlcNAc modiﬁcation can dynamically and inducibly be trans-
ferred to, and removed from, proteins, and has been shown to be
involved in signalling processes [3–5]. The O-GlcNAc modiﬁcation
is carried out by an enzyme called O-GlcNAc transferase (OGT) that
utilises the nucleotide sugar donor UDP-GlcNAc, produced through
the hexosamine biosynthetic pathway, to exclusively modify ser-
ine/threonine residues. OGT was ﬁrst discovered in human, rat
and the nematode Caenorhabditis elegans [6,7], subsequently de-
scribed in Arabidopsis thaliana [8] and very recently in Giardia
and Cryptosporidium parvum [9]. The O-GlcNAc modiﬁed protein
can be transformed back into its native state by O-GlcNAc hydroly-
sis by O-GlcNAcase (OGA). OGA has been characterised in human,
mouse, rat, Drosophila and C. elegans and was shown to be encoded
by a single gene [10–14]. In all metazoa, O-GlcNAc modiﬁed pro-
teins have been found in all functional classes [15,16,5]. Dynamic
interplay between protein O-GlcNAcylation and phosphorylation
has been observed on a number of proteins [17]. Speciﬁc Ser/Thral Societies. Published by Elsevier
.F. van Aalten).residues show reciprocal, same-site occupancy by phosphorylation
or O-GlcNAcylation (e.g. c-myc and oestrogen receptor-b or tau-
protein) or alternatively adjacent Ser/Thr residues can be occupied
by O-GlcNAcylation and phosphorylation (e.g. p53-protein) [17].
For the past decade PUGNAc and streptozotocin (STZ), both
inhibitors of the human OGA (hOGA), have been extensively used
to raise cellular O-GlcNAc levels to study the function of protein
O-GlcNAcylation [18,19]. Recently, it was discovered that NAG-
thiazoline, a transition state analogue, can also be used in cell-
based assays to potently inhibit hOGA [20]. However, all three
compounds have disadvantages. PUGNAc and NAG-thiazoline were
originally identiﬁed as potent inhibitors of human lysosomal
hexosaminidases (HexA/B), members of the glycoside hydrolase
family 20 (GH20) [21,22]. Recent kinetic and structural data ob-
tained from hOGA and bacterial homologues (GH84 family mem-
bers) have revealed that GH84 and GH20 perform hydrolysis via
substrate-assisted catalysis and the active site architecture is
structurally conserved [23–25]. Thus it is not surprising that hOGA
and HexA/B are equally potently inhibited by NAG-thiazoline and
PUGNAc. PUGNAc is a promiscuous inhibitor, targeting multiple
enzymes from functionally related glycoside hydrolase families,
including retaining a- and b-glucosaminidases from GH89 and
GH3, respectively [26,27]. Consequently, in cell-based studies
PUGNAc shows off-target effects, as shown recently by Macauley
et al. [28]. The authors also used a 600-fold selective thiazoline
derivative (NButGT) to inhibit hOGA in 3T3-L1 adipocytes. Whilst
both compounds increased cellular O-GlcNAcylation levels, only
the non-selective PUGNAc caused insulin resistance in 3T3-L1 adi-
pocytes [28]. STZ, another weak inhibitor of hOGA, carries a reac-
tive N-methylnitrosourea moiety that has been shown to be toxicB.V. Open access under CC BY license. 
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lease [32]. STZ was shown to be particularly toxic to pancreatic b
cells that secrete insulin, and it has since been used extensively
to create animal models of type I diabetes [33]. However, several
studies have shown that STZ toxicity does not correlate with hOGA
inhibition, suggesting that STZ-dependent b-cell toxicity occurs
independent of hOGA inhibition [34–36,31].
hOGA has so far resisted production in pure recombinant form
with yields required for protein crystallography. Two bacterial
apparent OGA orthologues from Clostridium perfringens and Bacte-
roides thetaiotaomicron have been studied by protein crystallogra-
phy to obtain insight in the active site and the catalytic
mechanism [24,37,25]. Recently, a series of NAG-thiazoline deriva-
tives, as well as GlcNAcstatins, a glucoimidazole-based class of
inhibitors, were described to inhibit hOGA potently and selectively
[28,38–40]. Crystal structures of the two bacterial OGAs in com-
plex with these compounds have been used to identify and itera-
tively improve protein–ligand interactions. However, all currently
known OGA inhibitors have in common a carbohydrate scaffold,
that is inherently non-drug-like when the Lipinski rules are consid-
ered [41] and not synthetically easily accessible for further optimi-
zation by medicinal chemistry. Thus, identiﬁcation of novel, more
drug-like, and synthetically accessible inhibitors of the GH84 en-
zymes could facilitate further efforts towards the identiﬁcation of
potent, cell permeable and metabolically stable OGA inhibitors.
Ideally, such compounds would be selective for GH84 enzymes
versus GH20 enzymes or could easily be modiﬁed to improve
selectivity towards hOGA. A possible approach to identify mole-
cules with these properties is by high-throughput screening. Here
we report the result of a screen, together with kinetic and struc-
tural studies of the hits, resulting in the discovery of novel, drug-
like scaffolds that competitively inhibit hOGA.2. Results and discussion
2.1. Identiﬁcation of novel OGA inhibitors from a high-throughput
screen
In order to identify new human O-GlcNAcase inhibitors, a high-
throughput screening assay was performed based on the release of
4-methylumbelliferol (4MU) from the pseudo substrate 4MU-Glc-
NAc, initially using the bacterial OGA homologue from C. perfrin-
gens (CpOGA) which has recently been shown to be a good model
of hOGA [24]. The CpOGA protein was screened against the library
from Prestwick Chemicals Inc. that contains 880 off-patent small
molecules. 85% of these compounds are currently marketed drugs.
These compounds were dissolved in 100% dimethyl sulfoxide
(DMSO) to generate library stocks with a ﬁnal a concentration of
2 mg/ml. With an average molecular weight of 377 Da, screening
assays were performed at an average concentration of 30.2 lM,
with a ﬁnal DMSO concentration of 1%. PUGNAc was used at a ﬁnal
concentration of 100 lM as a positive control. Probable false posi-
tives were identiﬁed by plotting the relative enzymatic activity
against the intrinsic absorbance of the compound at the ﬂuores-
cence excitation wavelength. After subtracting the intrinsic ﬂuo-
rescent signal from the compounds, the relative activity of
CpOGA in presence of the compounds in the screen was plotted
against the real ﬂuorescent signal from the reaction product
(Fig. 1A). Surprisingly, a large number of compounds clustered
around a relative activity of 0.6 (Fig. 1A) and not, as expected,
around 1.0. This may be caused by the fact that those compounds
are real inhibitors with much smaller molecular weights than the
average 377 Da and were thus screened at effective concentrations
higher than 30.2 lM. Only compounds that showed inhibition
>60% at the assumed concentration of 30.2 lM (equal to a relativeactivity smaller than 0.4) were considered for further analysis and
prioritised by the presence of chemical features likely to be com-
patible with the GH84 active site.
2.2. Selected screening hits competitively inhibit CpOGA in the
micromolar range
A number of compounds that inhibit CpOGA at the assumed
screening concentration of 30.2 lM to more than 60% were se-
lected from the Prestwick screen hits (Fig. 1A). Streptozotocin
(STZ), a known hOGA and CpOGA inhibitor [31], was identiﬁed from
the screen. The most potent compound was ketoconazole, followed
by semustine (Fig. 1A). Buspirone, STZ and diprophylline show sim-
ilar inhibition under the screening conditions, followed by aceta-
zolamide (Fig. 1A). All these compounds were commercially
available. 6-Methylaminopurine, a derivative of the weak (30%
inhibition) hit 6-benzylaminopurine, was also purchased, given
the recently published purine derivatives that inhibit chitinases,
enzymes that are mechanistically related to OGA [42,43,24]. The
molecular weights of the resulting selected compounds (Fig. 1B)
were used to calculate the true screening concentration (Table 1).
The compounds were then evaluated for CpOGA inhibition using
a dose–response experiment (Table 1). Ketoconazole appears to
be the most potent CpOGA inhibitor with an IC50 of 2 lM. N6-meth-
yladenine inhibits with an IC50 of 21 lM, whilst semustine, buspi-
rone and diprophylline inhibit with an IC50 of 39 lM, 50 lM and
60 lM, respectively. The dose–response curve of acetazolamide
yields an IC50 of 80 lM. The ranking of the levels of inhibition of
these compounds is the same from the screening and IC50 data.
Further kinetic experiments addressed the inhibition mode of
the four most potent compounds (diprophylline, ketoconazole,
semustine and N6-methyladenine) against CpOGA. Steady state
kinetics were measured to determine the inhibition mode and
the corresponding inhibition constant, Ki. Concentrations of the
inhibitors were chosen according to the previously determined
IC50 values (Table 1). For all four compounds, Lineweaver–Burk
analysis indicated that the pseudo-substrate 4MU-GlcNAc and
the compounds compete for binding to the same CpOGA active site
(Fig. 1C, Table 1). The absolute inhibition constants against CpOGA
measured for diprophylline (Ki = 25 lM), semustine (Ki = 23 lM)
and N6-methyladenine (Ki = 14 lM) are in good agreement with
the IC50 data (Table 1). Interestingly, N6-methyladenine is the most
potent CpOGA inhibitor identiﬁed, despite having the lowest
molecular weight (Table 1).
2.3. N6-methyladenine is an efﬁcient, selective, micromolar hOGA
inhibitor
The objective of this study was to identify new chemical scaf-
folds that are inhibitors of hOGA. Thus, inhibition studies of the
Prestwick screen-derived CpOGA inhibitors (Fig. 1B) were carried
out using recombinant hOGA protein (Fig. 1D). Both ketoconazole
and N6-methyladenine inhibit hOGA with IC50 values of 4 lM (Ta-
ble 1). Buspirone and acetazolamide inhibit hOGA with IC50 values
of 25 and 47 lM, whilst diprophylline and semustine are weak
hOGA inhibitors with inhibition constants of 120 and 260 lM.
Compared to the inhibition constants obtained against CpOGA
(Table 1), only the inhibition constant for semustine is signiﬁcantly
higher for hOGA than for CpOGA. The IC50 values determined for
acetazolamide, buspirone and ketoconazole against hOGA protein
are in agreement with the inhibition constants determined for
CpOGA (Table 1). However, N6-methyladenine appears to more po-
tently inhibit the human enzyme (IC50 = 4 lM for hOGA, vs. 21 l
for CpOGA, Table 1). Since the active site architecture of CpOGA
and hOGA are closely related [24], it is assumed that the inhibitors
bind to hOGA competitively, as determined for CpOGA. Therefore,
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Fig. 1. (A) Prestwick library screen against CpOGA. The scatter-plot shows on the horizontal axis the remaining activity of CpOGA in presence of the compounds (measured by
the liberation of 4MU) and on the vertical axis the intrinsic absorbance/ﬂuorescence of the compounds at the excitation and emission wavelength (360 nm/460 nm). Points in
the lower left corner indicate compounds that do not absorb at the excitation wavelength, yet do exhibit reduced ﬂuorescence and thus reduce CpOGA activity. Six
compounds are labelled in coloured dots, according to the legend in the graph. (B) Chemical structures of compounds selected with the aid of the Prestwick screening data: (a)
N6-methyladenine, (b) diprophylline, (c) acetazolamide, (d) semustine, (e) streptozotocin (STZ), (f) ketoconazole and (g) buspirone. (C) Diprophylline is a competitive
inhibitor of CpOGA. Steady-state kinetic data (triplicates) using 0.2 nM CpOGA, 0–25 lM substrate (4MU-GlcNAc), 0–110 l inhibitor and 7 min reaction time were ﬁtted using
the standard equation for competitive inhibition in the GraFit program [52]. (D) Dose–response curves of the selected compounds against hOGA. Data obtained with the 4MU-
GlcNAc assay (2 nM hOGA, 80 lM 4MU-GlcNAc, 0.7 nM–100 lM inhibitor, 60 min reaction time) from buspirone, diprophylline and acetazolamide, semustine, N6-
methyladenine and ketoconazole were ﬁtted using the standard IC50 equation in the GraFit program [52].
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Table 1
Screening data, inhibition constants and binding efﬁciency obtained for the selected compounds.
Compound MW
(Da)
Screening
(lM)
CpOGA IC50 (lM) CpOGA Ki
(lM)
hOGA IC50
(lM)
HexA/B IC50
(lM)
Selectivity
(HexA/B/hOGA)
hOGA
BEIa,b
Acetazolamide 222 90 80 ± 14 n.d. 47.0 ± 0.1 32 ± 2 0.7 21
Buspirone 386 52 50 ± 15 n.d. 25.0 ± 0.1 47 ± 3 1.9 13
Diprophylline 254 79 60 ± 10 25 ± 2 121 ± 10 200 ± 30 1.6 16
Ketoconazole 531 38 2.0 ± 0.4 15 ± 5 4.3 ± 0.4 11 ± 1 2.6 11
Semustine 248 81 39 ± 6 23 ± 7 262 ± 6 2500 9 16
N6-methyladenine 149 – 21 ± 4 14 ± 1 4.0 ± 0.3 300 75 34
Streptozotocin 265 87 30c n.d. 1500d 45000 30 11
NAG-thiazoline 219 – – n.d. 0.07d 0.07d 1.0 32
PUGNAc 353 – – 0.005e 0.05d 0.05d 1.0 21
a BEI Binding Efﬁciency Index (BEI) [46] calculated for hOGA inhibition, BEI = log(Ki)/M,with M being the mass of the compound in kDa.
b The Cheng–Prusoff equation (Ki = IC50/1 + ([S]/Km)) was used to convert the IC50 values to anabsolute inhibition constant (Ki).
c Data taken from [31].
d Ki value from [20].
e Ki value from [24].
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IC50 < 50 lM have been identiﬁed from screening the Prestwick
Chemical library with the bacterial homologue CpOGA.
Ligand efﬁciency is a powerful tool to evaluate the usefulness of
a scaffold as a starting point for further medicinal chemistry [44–
46]. The binding efﬁciency index (BEI) [46] was calculated for all
drug-like O-GlcNAcase scaffolds and compared to the BEI of well
known potent hOGA inhibitors NAG-thiazoline and PUGNAc (Table
1). Interestingly, while the small compound N6-methyladenine is a
weaker inhibitor of hOGA than PUGNAc and NAG-thiazoline inY335
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Fig. 2. (A) Stereo ﬁgure of diprophylline in the active site of CpOGA. The CpOGA active si
the compound, as sticks with grey carbon, red oxygen and blue nitrogen atoms. Dipro
Hydrogen bonds between the ligand and the protein are indicated by black dashed lines.
(B) Stereo view of the superimposed crystallographically determined complexes of CpO
depicted in sticks with cyan carbon, red oxygen and blue nitrogen atoms). Hydrogen boabsolute terms, in terms of ligand efﬁciency it, with a BEI of 34
(NAG-thiazoline and PUGNAc show a BEI of 32 and 21, respec-
tively), is a more efﬁcient binder.
To investigate whether the compounds identiﬁed from the
Prestwick library screen display selectivity for hOGA over the clo-
sely related lysosomal hexosaminidases A/B (HexA/B), the enzy-
matic activity of HexA/B in the presence of each the compounds
was analysed (Table 1). Ketoconazole, acetazolamide and buspi-
rone were determined to have inhibition constants between
IC50 = 10 lM and 50 lM (Table 1). Comparison of these inhibitionY335
D298
D297
D401
W39
N396N429
K218
W49
Y335
D298
D297
D401
W39
G187
N396N429
V331
W49
K218
te is shown with residues contributing to diprophylline binding and/or surrounding
phylline is depicted in sticks with green carbon, red oxygen, blue nitrogen atoms.
Unbiased jFoj  jFCj, /calc electron density (2.75 r) for diprophylline is shown in cyan.
GA with diprophylline (colour scheme as in panel (A) and STZ (PDB entry 2VUR,
nds between the protein and diprophylline are indicated by black dashed lines.
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selectivity for the human O-GlcNAcase (Table 1). Similarly, dipro-
phylline, with an inhibition constant of IC50 = 200 lM for HexA/
B, is not selective for hOGA. Interestingly, a 75-fold selectivity is
observed for N6-methyladenine (IC50 = 300 lM for HexA/B vs.
4 lM for hOGA, Table 1).
2.4. Diprophylline mimics substrate binding in the OGA active site
To determine the binding mode of the competitive OGA inhibi-
tors, these compounds were soaked into CpOGA crystals. Ordered
electron density could only be obtained for diprophylline. Diproph-
ylline is a xanthine derivative that consists of two moieties. The
xanthine moiety is methylated on the N1 and N3 ring atoms
(Fig. 1B). Furthermore, the N7 atom is modiﬁed with a (2,3-dihydr-
oxypropyl) moiety that possesses a stereo centre at the carbon of
the secondary alcohol (Fig. 1B). The electron density for the inhib-
itor was located in the active site of CpOGA, where it competes
with substrate binding, in agreement with the competitive inhibi-
tion mode determined from kinetic studies. Diprophylline interacts
with three active site residues via hydrogen bonds (Fig. 2A). The 2-
OH and 3-OH hydroxyl groups from the 2,3-dihydroxypropyl moi-
ety hydrogen bond to the carboxyl group of residue Asp401, which
is conserved between bacterial (CpOGA) and hOGA (Fig. 2A). This
interaction mimics the interaction of GlcNAc 4/6-OH with
Asp401 (Fig. 2A and B). The xanthine moiety is sandwiched be-
tween the two aromatic residues Trp394 and Tyr335, where it par-
ticipates in p-stacking interactions (Fig. 2A). Furthermore, Lys218
and Asn396 hydrogen bond to the N9 and O6 atoms from the the-
ophylline moiety, respectively (Fig. 2A). The electron density
unambiguously represented the S-enantiomer of diprophylline
(Fig. 2A).
The overall active site of the diprophylline-CpOGA complex is in
the same arrangement observed for the unliganded [24] and the
STZ-CpOGA complex [31] (Fig. 2B). Interestingly, the loop carrying
the catalytic acid Asp298 and Asp297 is in the ‘open’ conformation.
The peptide bond of Asp297–Asp298 is in the same conformation
as described for the apo structure [24] and the STZ-liganded struc-
ture [31], thus the backbone carbonyl from Asp297 points into the
active site and the side chain of Asp298 points out of the active site.
Comparison of the STZ-CpOGA complex with the diprophylline-
CpOGA complex reveals only minor differences in terms of the pro-
tein conformation. The loop carrying Asp297 and Asp298 has
moved closer into the active site (maximum atomic shift = 1.2 Å),
but neither Asp297 nor Asp298 interact with the compound.
Superposition reveals that the O6 carbonyl group of diprophylline
occupies the same position as the carbonyl oxygen of STZ (posi-
tional shift = 0.35 Å), and accepts a similar hydrogen bond from
Nd2 of (the conserved) Asn396 at the back of the active site
(Fig. 2A and B).3. Concluding remarks
Screening a bacterial homologue of hOGA against a small com-
mercial library from Prestwick Chemicals Inc. has resulted in the
discovery of the ﬁrst inhibitors of human O-GlcNAc that do not ex-
hibit a sugar-like scaffold (Fig. 1B). Four of the these molecules
competitively inhibit the GH84 enzymes. Interestingly, the small
molecule N6-methyladenine, is a potent hOGA inhibitor
(IC50 = 4 lM and shows 75-fold selectivity for the hOGA enzyme
over the lysosomal hexosaminidases. This compound could be a
lead for chemical modiﬁcation to increase both the selectivity
and potency of inhibition. Since no structural data was obtained,
interactions of N6-methyladenine with the GH84 active site remain
unknown. Interestingly, recent studies have described the bindingof xanthine-like compounds to the active site of Aspergillus fumig-
atus chitinase 1 B (AfChiB) [47] and a virtual screening-based ap-
proach that resulted in the synthesis of a derivative with
micromolar inhibition [43]. A similar strategy could be applied to
N6-methyladenine, which binds with a BEI of 34 to the hOGA active
site.
Diprophylline, another xanthine-based molecule, was identiﬁed
as a micromolar inhibitor for hOGA and the binding mode was
structurally determined. Only the S-isoform of diprophylline binds
to the GH84 active site and interacts with several residues con-
served between hOGA and CpOGA (Fig. 2A and B). Diprophylline
is an interesting lead that could be further exploited by struc-
ture-based design to generate more potent derivatives that may in-
hibit hOGA in vivo.
In summary, this study shows that it is possible to identify
hOGA inhibitors with scaffolds different from a sugar core, with
promising properties in terms of synthetic accessibility, potency
and selectivity. This will stimulate future work, both in terms of
a medicinal chemistry exploration of these scaffolds, and the iden-
tiﬁcation of more potent inhibitors by screening campaigns on lar-
ger libraries.4. Materials and methods
4.1. Cloning, expression and puriﬁcation
CpOGA and hOGA protein were expressed and puriﬁed follow-
ing the protocol described previously [24,39,31,40].
4.2. Determination of the CpOGA-diprophylline complex structure
CpOGA crystals were produced as described previously [24].
Precipitant was carefully removed and solid diprophylline was
added straight to the drop. After 30 min the crystal was removed
and cryo-protected in mother liquor containing 15% glycerol. Dif-
fraction data were collected to 2.25 Å at the ESRF, Grenoble on
ID14-3, and processed with the HKL suite [48], resulting in a data
set with 99.9% completeness (100% in the highest resolution shell)
with an overall Rmerge of 0.071 (0.535 in the highest resolution
shell). Reﬁnement was initiated using a native CpOGA structure
(PDB-code 2CBI), immediately revealing well deﬁned jFoj  jFcj,
/calc electron density for the inhibitor, which was built with the
help of a structure and topology generated by PRODRG [49]. Fur-
ther model building with COOT [50]) and reﬁnement with REFMAC
[51] then yielded the ﬁnal model with good statistics (R, Rfree: 19.8,
24.7).
4.3. Inhibitor library screening
Puriﬁed CpOGA protein was screened against a commercial li-
brary (Prestwick Chemicals Inc. France) containing 880 off-patent
small molecules (85% of which are marketed drugs). The com-
pounds were stored in 100% dimethyl sulfoxide (DMSO) at a con-
centration of 2 mg/ml – CpOGA hydrolyses 4MU-GlcNAc without
signiﬁcant loss of activity at up to 4% DMSO. 0.5 ll aliquots of
the compounds from the library were pipetted into 96 well-plates.
44.5 ll of the standard reaction mixture containing CpOGA protein
at a ﬁnal concentration of 0.2 nM (in 50 ll ﬁnal reaction volume)
was added to the compounds. 5 ll of the ﬂuorescent substrate
4MU-NAG was added in a 10-fold concentration (32 lM) to initiate
the reaction after a 5 min incubation time of the CpOGA enzyme
with the compound. The reaction was stopped after 7 min at RT
(20 C) using standard procedure and the ﬂuorescent signal was
measured using the standard procedure described previously
[24,31,39,40]. Hits were selected using several criteria: the com-
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screened and to posses a chemical scaffold with chemical features
compatible with binding to the active site of GH84 enzymes.
4.4. Inhibition measurements of CpOGA, hOGA and human HexA/B
Further kinetic experiments to determine the mode of inhibi-
tion were carried out according to the procedure described
previously [40]. Ketoconazole, acetazolamide, buspirone, diproph-
ylline, N6-methyladenine, streptozotocin and semustine were pur-
chased from Sigma. IC50 measurements with CpOGA, hOGA and a
mixture of human hexosaminidase A/B activities (Sigma A6152)
against the compounds were performed using the ﬂuorogenic
4MU-NAG substrate and standard reaction mixtures as described
previously with some changes [39,31,40]. Standard reaction mix-
tures (50 ll) contained 0.2 nM CpOGA, 2 nM hOGA or 50 l units
unit/ml HexA/B in McIlvaine buffer (0.2 M Na2HPO4 mixed with
0.1 M citric acid to pH 5.7) supplemented with 0.1 mg/ml BSA.
IC50 determinations were carried out using substrate concentra-
tions corresponding to the Km established for CpOGA (2.9 lM),
hOGA (80 lM) and HexA/B (230 lM). The reactions were run at
room temperature for 7 min (CpOGA), 60 min (hOGA) or 15 min
(HexA/B). Determination of the Ki for CpOGA was performed by
steady-state kinetics using the parameters described for CpOGA
IC50 determinations with a series of inhibitor concentrations (0–
110 lM. The reactions were stopped by the addition of 100 ll
3 M glycine–NaOH, pH 10.3. The ﬂuorescence of the released
4MU was quantiﬁed as described previously [39,31,40]. Ki experi-
ments were performed in triplicate and IC50 determinations with
single data points for a series of 18 concentrations between
0.7 nM and 100 lM.
Acknowledgments
We thank the European Synchrotron Radiation Facility, Greno-
ble, for the time at beamline ID14-3. We would like to thank Adel
Ibrahim (University of Dundee, Cloning Service, DSTT) for cloning
of the human OGA construct and Sharon Shepherd and Mark Dor-
ward for protein expression and puriﬁcation. We would like to
thank Willem van Heugten for help with crystallographic reﬁne-
ment. This work was supported by a Wellcome Trust Senior Fel-
lowship and a Lister Institute for Preventive Medicine Research
Prize. H.C.D. is supported by the College of Life Sciences Alumni
Studentship. The coordinates and structure factors have been
deposited with the PDB (PDB entry 2x0y).
References
[1] Torres, C.R. and Hart, G.W. (1984) Topography and polypeptide distribution of
terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes
– evidence for O-linked GlcNAc. J. Biol. Chem. 259, 3308–3317.
[2] Hart, G.W., Haltiwanger, R.S., Holt, G.D. and Kelly, W.G. (1989) Nucleoplasmic
and cytoplasmic glycoproteins. Ciba Found. Symp. 145, 102–112. di.
[3] Roquemore, E.P., Chevrier, M.R., Cotter, R.J. and Hart, G.W. (1996) Dynamic O-
GlcNAcylation of the small heat shock protein a b-crystallin. Biochemistry 35
(11), 3578–3586.
[4] Chou, C.F., Smith, A.J. and Omary, M.B. (1992) Characterization and dynamics
of o-linked glycosylation of human cytokeratin 8 and 18. J. Biol. Chem. 267 (6),
3901–3906.
[5] Zachara, N.E., Hart, G.W. and signaling, Cell (2006) the essential role of o-
GlcNAc! Biochim. Biophys. Acta 1761, 599–617.
[6] Kreppel, L., Blomberg, M. and Hart, G. (1997) Dynamic glycosylation of nuclear
and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc
transferase with multiple tetra-tricopeptide repeats. J. Biol. Chem. 272, 9308–
9315.
[7] Lubas, W., Frank, D., Krause, M. and Hanover, J. (1997) O-Linked GlcNAc
transferase is a conserved nucleocytoplasmic protein containing
tetratricopeptide repeats. J. Biol. Chem. 272, 9316–9324.
[8] Jacobsen, S.E., Binkowski, K.A. and Olszewski, N.E. (1996) SPINDLY, a
tetratricopeptide repeat protein involved in gibberellin signal transduction
in Arabidopsis. Proc. Natl. Acad. Sci. USA 93 (17), 9292–9296.[9] Banerjee, S., Robbins, P.W. and Samuelson, J. (2009) Molecular characterization
of nucleocytoso-lic O-GlcNAc transferases of Giardia lamblia and
Cryptosporidium parvum. Glycobiology 19 (4), 331–336.
[10] Gao, Y., Wells, L., Comer, F.I., Parker, G.J. and Hart, G.W. (2001) Dynamic O-
glycosylation of nuclear and cytosolic proteins – cloning and characterization
of a neutral, cytosolic b-N-acetylglucosaminidase from human brain. J. Biol.
Chem. 276, 9838–9845.
[11] Comtesse, N., Maldener, E. and Meese, E. (2001) Identiﬁcation of a nuclear
variant of MGEA5, a cytoplasmic hyaluronidase and a b-N-
acetylglucosaminidase. Biochem. Biophys. Res. Commun. 283 (3), 634–640.
[12] Dong, D.L.Y. and Hart, G.W. (1994) Puriﬁcation and characterization of an O-
GlcNAc selective N-acetyl-b-D-glucosaminidase from rat spleen cytosol. J. Biol.
Chem. 269, 19321–19330.
[13] Kelly, W.G. and Hart, G.W. (1989) Glycosylation of chromosomal proteins:
localization of O-linked N-acetylglucosamine in Drosophila chromatin. Cell 57
(2), 243–251.
[14] Forsythe, M.E., Love, D.C., Lazarus, B.D., Kim, E.J., Prinz, W.A., Ashwell, G.,
Krause, M.W. and Hanover, J.A. (2006) Caenorhabditis elegans ortholog of a
diabetes susceptibility locus: oga-1 (o-GlcNAcase) knockout impacts o-GlcNAc
cycling, metabolism, and dauer. Proc. Natl. Acad. Sci. USA 103, 11952–11957.
[15] Wells, L., Vosseller, K. and Hart, G.W. (2001) Glycosylation of
nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291
(5512), 2376–2378.
[16] Love, D.C. and Hanover, J.A. (2005) The hexosamine signaling pathway:
deciphering the ‘‘O-GlcNAc code”. Sci. STKE 312, 1–14.
[17] Hart, G.W., Housley, M.P. and Slawson, C. (2007) Cycling of O-linked b-N-
acetylglucosamine on nucleocytoplasmic proteins. Nature 446, 1017–1022.
[18] Haltiwanger, R.S., Grove, K. and Philipsberg, G.A. (1998) Modulation of O-
linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo
using the peptide O-GlcNAc-b-N-acetylglucosaminidase inhibitor O-(2-
acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J.
Biol. Chem. 273, 3611–3617.
[19] Liu, K., Paterson, A.J., Chin, E. and Kudlow, J.E. (2000) Glucose stimulates
protein modiﬁcation by o-linked GlcNAc in pancreatic b cells: linkage of o-
linked GlcNAc to b cell death. Proc. Natl. Acad. Sci. USA 97, 2820–2825.
[20] Macauley, M.S., Whitworth, G.E., Debowski, A.W., Chin, D. and Vocadlo, D.J.
(2005) O-GlcNAcase uses substrate-assisted catalysis – kinetic analysis and
development of highly selective mechanism-inspired inhibitors. J. Biol. Chem.
280, 25313–25322.
[21] Horsch, M., Hoesch, L., Vasella, A. and Rast, D.M. (1991) N-
acetylglucosaminono-1,5-lactone oxime and the corresponding
(phenylcarbamoyl)oxime – novel and potent inhibitors of b-N-
acetylglucosaminidase. Eur. J. Biochem. 197, 815–818.
[22] Knapp, S., Vocadlo, D., Gao, Z., Kirk, B., Lou, J. and Withers, S.G. (1996) NAG-
thiazoline, an N-acetyl-b-hexosaminidase inhibitor that implicates acetamido
participation. J. Am. Chem. Soc. 118, 6804–6805.
[23] Cetinbas, N., Macauley, M.S., Stubbs, K.A., Drapala, R. and Vocadlo, D.J. (2006)
Identiﬁcation of asp174 and asp175 as the key catalytic residues of human
o-glcnacase by functional analysis of site-directed mutants. Biochemistry 45
(11), 3835–3844.
[24] Rao, F.V., Dorfmueller, H.C., Villa, F., Allwood, M., Eggleston, I.M. and van
Aalten, D.M.F. (2006) Structural insights into the mechanism and inhibition of
eukaryotic O-GlcNAc hydrolysis. EMBO J. 25, 1569–1578.
[25] Dennis, R.J., Taylor, E.J., Macauley, M.S., Stubbs, K.A., Turkenburg, J.P., Hart, S.J.,
Black, G.N., Vocadlo, D.J. and Davies, G.J. (2006) Structure and mechanism of a
bacterial b-glucosaminidase having O-GlcNAcase activity. Nat. Struct. Mol.
Biol. 13, 365–371.
[26] Stubbs, K.A., Balcewich, M., Mark, B.L. and Vocadlo, D.J. (2007) Small molecule
inhibitors of a glycoside hydrolase attenuate inducible AmpC mediated
b-lactam resistance. J. Biol. Chem.
[27] Ficko-Blean, E., Stubbs, K.A., Nemirovsky, O., Vocadlo, D.J. and Boraston, A.B.
(2008) Structural and mechanistic insight into the basis of
mucopolysaccharidosis IIIB. Proc. Natl. Acad. Sci. USA 105 (18), 6560–6565.
[28] Macauley, M.S., Bubb, A.K., Martinez-Fleites, C., Davies, G.J. and Vocadlo, D.J.
(2008) Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective
inhibition of O-GlcNAcase does not induce insulin resistance. J. Biol. Chem.
283 (50), 34687–34695.
[29] Junod, A., Lambert, A.E., Orci, L., Pictet, R., Gonet, A.E. and Renold, A.E. (1967)
Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med.
126 (1), 201–205.
[30] Bennett, R.A. and Pegg, A.E. (1981) Alkylation of DNA in rat tissues following
administration of streptozotocin. Cancer Res. 41 (7), 2786–2790.
[31] Pathak, S., Dorfmueller, H.C., Borodkin, V.S. and Van Aalten, D.M.F. (2008)
Chemical dissection of the link between streptozotocin, O-GlcNAc, and
pancreatic cell death. Chem. Biol. 15, 799–807.
[32] Kroncke, K.D., Fehsel, K., Sommer, A., Rodriguez, M.L. and Kolb-Bachofen, V.
(1995) Nitric oxide generation during cellular metabolization of the
diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet
cell DNA damage. Biol. Chem. Hoppe-Seyler 376 (3), 179–185.
[33] Mansford, K.R. and Opie, L. (1968) Comparison of metabolic abnormalities in
diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1, 670–671.
[34] Gao, Y., Parker, G.J. and Hart, G.W. (2000) Streptozotocin-induced b-cell death
is independent of its inhibition of O-GlcNAccase in pancreatic min6 cells. Arch.
Biochem. Biophys. 383, 296–302.
[35] Kaneto, H., Xu, G., Song, K.H., Suzuma, K., Bonner-Weir, S., Sharma, A. and
Weir, G.C. (2001) Activation of the hexosamine pathway leads to deterioration
700 H.C. Dorfmueller, D.M.F. van Aalten / FEBS Letters 584 (2010) 694–700of pancreatic b-cell function through the induction of oxidative stress. J. Biol.
Chem. 276, 31099–31104.
[36] Okuyama, R. and Yachi, M. (2001) Cytosolic O-GlcNAc accumulation is not
involved in b-cell death in HIT-T15 or Min6. Biochem. Biophys. Res. Commun.
287, 366–371.
[37] Ficko-Blean, E., Gregg, K.J., Adams, J.J., Hehemann, J.-H., Czjzek, M., Smith, S.P.
and Boraston, A.B. (2009) Portrait of an enzyme, a complete structural analysis
of a multimodular beta-N-acetylglucosaminidase from Clostridium perfringens.
J. Biol. Chem. 284 (15), 9876–9884.
[38] Yuzwa, S., Macauley, M., Heinonen, J., Shan, X., Dennis, R., He, Y., Whitworth,
G., Stubbs, K., McEachern, E., Davies, G. and Vocadlo, D. (2008) A potent
mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of
tau in vivo. Nat. Chem. Biol. 4, 483–490.
[39] Dorfmueller, H.C., Borodkin, V.S., Schimpl, M., Shepherd, S.M., Shpiro, N.A. and
van Aalten, D.M.F. (2006) GlcNAcstatin: a picomolar, selective O-GlcNAcase
inhibitor that modulates intracellular O-GlcNAcylation levels. J. Am. Chem.
Soc. 128, 16484–16485.
[40] Dorfmueller, H.C., Borodkin, V.S., Schimpl, M. and van Aalten, D.M.F. (2009)
GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing
cellular hyper-O-GlcNAcylation. Biochem. J. 420 (2), 221–227.
[41] Lipinski, C.A. (2000) Drug-like properties and the causes of poor solubility and
poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249.
[42] Rao, F.V., Andersen, O.A., Vora, K.A., DeMartino, J.A. and van Aalten, D.M.F.
(2005) Methylxanthine drugs are chitinase inhibitors: investigation of
inhibition and binding modes. Chem. Biol. 12, 973–980.[43] Schuettelkopf, A.W., Andersen, O.A., Rao, F.V., Allwood, M., Lloyd, C., Eggleston,
I.M. and van Aalten, D.M.F. (2006) J. Biol. Chem. 281, 27278–27285.
[44] Kuntz, I.D., Chen, K., Sharp, K.A. and Kollman, P.A. (1999) The maximal afﬁnity
of ligands. Proc. Nat. Acad. Sci. USA 96, 9997–10002.
[45] Hopkins, A.L., Groom, C.R. and Alex, A. (2004) Ligand efﬁciency: a useful metric
for lead selection. Drug Discov. Today 9, 430–431.
[46] Abad-Zapatero, C. and Metz, J.T. (2005) Ligand efﬁciency indices as guideposts
for drug discovery. Drug Discov. Today 10 (7), 464–469.
[47] Rao, F.V., Houston, D.R., Boot, R.G., Aerts, J.M.F.G., Hodkinson, M., Adams, D.J.,
Sh-iomi, K., Omura, S. and van Aalten, D.M.F. (2005) Speciﬁcity and afﬁnity of
natural product cyclopentapeptide inhibitors against A. fumigatus, human, and
bacterial chitinases. Chem. Biol. 12, 65–76.
[48] Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276, 307–326.
[49] Schuettelkopf, A.W. and van Aalten, D.M.F. (2004) PRODRG: a tool for high-
throughput crystallography of protein-ligand complexes. Acta Cryst. D60,
1355–1363.
[50] Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular
graphics. Acta Cryst. D60, 2126–2132.
[51] Murshudov, G.N., Vagin, A.A. and Dodson, E.J. (1997) Reﬁnement of
macromolecular structures by the maximum-likelihood method. Acta Cryst.
D53, 240–255.
[52] Leatherbarrow, R.J. (2001) GraFit. Version 5, Erithacus Software Ltd., Horley,
U.K.
